Phio Pharmaceuticals director buys 10,000 shares

Q: How many shares did a PHIO director purchase?

Ronald Todd Plott, a director, reported purchases of 10,000 PHIO common shares: 5,000 shares on September 28, 2026, and 5,000 shares on September 29, 2026.

Q: What prices did the PHIO director pay for the shares?

Ronald Todd Plott reported a purchase price of $1.03 per share on September 28, 2026, and $1.04 per share on September 29, 2026.

The reported transactions were direct purchases, and the Rule 10b5-1 plan checkbox was unchecked.

Filing Impact

(Neutral)

Filing Sentiment

(Positive)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Phio Pharmaceuticals Corp. (PHIO) director Ronald Todd Plott reported direct purchases of 5,000 common shares on September 28, 2026, at $1.03 per share and 5,000 shares on September 29, 2026, at $1.04 per share. The Rule 10b5-1 plan checkbox was unchecked.

Insider Trade Summary

Net Buyer: 10,000 shares

Net Buy 2 txns

Insider Plott Ronald Todd

Role Director

Bought 10,000 shs ($10K)

Type	Security	Shares	Price	Value
Purchase	Common Stock, $.0001 par value ^F1	5,000	$1.04	$5K
Purchase	Common Stock, $.0001 par value ^F1	5,000	$1.03	$5K

Holdings After Transaction: Common Stock, $.0001 par value — 42,000 shares (Direct)

Footnotes (1)

F1. Includes shares of common stock underlying unvested restricted stock units.

Key Figures

Shares purchased: 5,000 shares Purchase price: $1.03 per share Shares purchased: 5,000 shares +1 more

4 metrics

Shares purchased 5,000 shares September 28, 2026

Purchase price $1.03 per share September 28, 2026

Shares purchased 5,000 shares September 29, 2026

Purchase price $1.04 per share September 29, 2026

Key Terms

non-derivative, restricted stock units

2 terms

non-derivative technical

"Common Stock; non-derivative transaction"

restricted stock units financial

"underlying unvested restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares did a PHIO director purchase?

Ronald Todd Plott, a director, reported purchases of 10,000 PHIO common shares: 5,000 shares on September 28, 2026, and 5,000 shares on September 29, 2026.

What prices did the PHIO director pay for the shares?

Ronald Todd Plott reported a purchase price of $1.03 per share on September 28, 2026, and $1.04 per share on September 29, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 09/30/2026 - 04:01 PM Accepted by SEC EDGAR 09/30/2026 - 04:01 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Plott Ronald Todd

(Last)

(First)

(Middle)

C/O PHIO PHARMACEUTICALS CORP

411 SWEDELAND RD., STE 23-1080

(Street)

KING OF PRUSSIA

PENNSYLVANIA

19406

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Phio Pharmaceuticals Corp. [ PHIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock, $.0001 par value	09/28/2026		P		5,000	A	$1.03	37,000⁽¹⁾	D
Common Stock, $.0001 par value	09/29/2026		P		5,000	A	$1.04	42,000⁽¹⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Includes shares of common stock underlying unvested restricted stock units.

	/s/ Lisa C. Carson, Attorney-in-fact	09/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR